Mitoxantrona Sandoz (Mitoxantrone)

Mitoxantrone intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the re‑ligation of DNA strands during replication. This creates double‑strand breaks, halting cell division and triggering apoptosis in rapidly dividing malignant or immune cells.

The dose of Mitoxantrona Sandoz is individualized by the prescribing physician based on the specific indication, disease severity, patient weight, renal and hepatic function, and prior treatment history. No fixed regimen is provided here.

Mitoxantrona Sandoz is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided in pregnant women and not used while breastfeeding because it can be excreted in milk and may harm the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mitoxantrona Sandoz offers a similar DNA‑intercalating mechanism to other anthracenedones but differs in its pharmacokinetic profile and approved indications. Compared with agents such as doxorubicin, mitoxantrone has a lower incidence of acute cardiotoxicity at equivalent doses, though long‑term monitoring remains essential.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Use aseptic technique when preparing the injectable solution, and keep the vial in its original packaging until use.

Mitoxantrona Sandoz is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a period of 30‑60 minutes, with dosing calculated by the treating physician.

Serious risks include cardiotoxicity (reduced left‑ventricular function), secondary acute leukemia, severe infections due to neutropenia, pulmonary toxicity such as interstitial pneumonitis, and hepatic failure. Patients should be monitored closely for these events throughout therapy.

Mitoxantrona Sandoz is contraindicated in patients with known hypersensitivity to mitoxantrone or any formulation component, in pregnant women, and in individuals with pre‑existing severe cardiac disease, uncontrolled infections, or significant hepatic impairment.